261 results on '"Christgen M"'
Search Results
2. Co-expression of transcription factor AP-2beta (TFAP2B) and GATA3 in human mammary epithelial cells with intense, apicobasal immunoreactivity for CK8/18
3. De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel
4. 18P A translational project of the WSG-ADAPT-TN trial demonstrates immunomodulatory and anti-viral defense gene networks predicting pathological complete response (pCR) and survival after de-escalated neoadjuvant chemotherapy (NACT) in early triple-negative breast cancer (eTNBC)
5. 120TiP Premenopausal women with breast cancer optimally treated with OFS (PROOFS)
6. Ektopien des Mammagewebes
7. Transmurale Nekrose des Fundus uteri nach septischem Abort – ein Fallbericht
8. HPV RNA analyses in sentinel and peripheral lymph nodes as potential diagnostic tool for metastatic cervical cancer
9. LBA14 Impact of age, recurrence score (RS) and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Analysis of ADAPT and ADAPTcycle trials
10. 237MO TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy without immunotherapy
11. LBA17 Survival outcome of neoadjuvant endocrine therapy + trastuzumab and pertuzumab (ET+T+P) vs. de-escalated chemotherapy (CT)+T+P in hormone receptor positive (HR+)/HER2+ early breast cancer (EBC): WSG-TP-II trial
12. Histologisches Grading beim Mammakarzinom
13. De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekly paclitaxel (vol 28, pg 2768, 2017)
14. Corrigendum to “De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel”
15. Endocrine response assessment by Ki67: Concordance of central versus local Ki67 measurements in the ADAPTcycle trial.
16. Resistenz gegenüber CD95-vermittelter Apoptose im duktalen Pankreasadenokarzinom: Die Rolle der Proteinkinase Cμ
17. Stanzbioptische Differenzialdiagnose von Spindelzelltumoren der Mamma
18. Proliferationsbestimmung beim Mammakarzinom durch den immunhistochemischen Nachweis von Ki-67
19. LBA13 Predictive impact of biomarkers on pCR and survival after de-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs. trastuzumab+ET in HER2+/HR+ early breast cancer: WSG ADAPT TP trial
20. Pathologische Komplettremissionsrate und Überleben von Patientinnen mit BRCA-assoziiertem triple-negativen Brustkrebs nach 12 Wochen anthrazyklinfreier neoadjuvanter Chemotherapie: Ergebnisse der WSG-ADAPT TN Studie (NCT01815242)
21. LBA2 Impact of RNA expression signatures and tumour infiltrating lymphocytes (TILs) for pathological complete response (pCR) and survival after 12 week de-escalated neoadjuvant pertuzumab + trastuzumab ± paclitaxel in the WSG-HER2+/HR- ADAPT trial
22. Predictive impact of biomarkers on pCR and survival after de-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs. trastuzumab+ET in HER2+/HR+ early breast cancer: WSG ADAPT TP trial
23. LBA24 Multiparametric prognostic score in early HR+/HER2- breast cancer: Impact of recurrence score, clinical-pathological factors, gene mutations and histology
24. Jenseits von Staging, Typing und Grading: Herausforderungen und Perspektiven für die Tumorpathologie der Mamma
25. Run-in phase of prospective WSG ADAPT HR+/HER2- trial demonstrates feasibility of early endocrine sensitivity prediction by Recurrence Score and conventional parameters in clinical routine.: ID 455
26. De-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs trastuzumab plus ET in early HR+/HER2+breast cancer (BC): ADAPT-TP survival results
27. High likelihood of actionable pDifferential impact of prognostic parameters in hormone receptor-positive lobular early breast cancer in the WSG PlanB trialathogenic variant detection in breast cancer genes in women with very early onset breast cancer, but low rate of additional panel genes
28. Differential impact of prognostic parameters in hormone receptor-positive lobular early breast cancer in the WSG PlanB trial
29. LBA14 De-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs trastuzumab+ET in early HR+/HER2+ breast cancer (BC): ADAPT-TP survival results
30. 164MO Impaired Ki67 response towards neoadjuvant endocrine therapy in luminal breast cancer is associated with mutations conferring endocrine resistance: WSG-ADAPT HR+/HER2- translational results
31. No survival benefit of chemotherapy escalation in patients with pCR and 'high-immune' triple-negative early breast cancer in the neoadjuvant WSG-ADAPT-TN trial
32. Resistenz gegenüber CD95-vermittelter Apoptose im duktalen Pankreasadenokarzinom: Die Rolle der Proteinkinase Cμ
33. ADAPTcycle – adjuvant dynamic marker-adjusted personalized therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate risk HR+/HER2- early breast cancer
34. Abstract GS5-06: No survival benefit of chemotherapy escalation in patients with pCR and “high-immune” triple-negative early breast cancer in the neoadjuvant WSG-ADAPT-TN trial
35. Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial
36. Impact of tumor-infiltrating lymphocytes on response to neoadjuvant chemotherapy in triple-negative early breast cancer: Translational subproject of the WSG-ADAPT TN trial
37. Calziphylaxie der Mamma – eine seltene Differentialdiagnose bei der Abklärung eines Tastbefundes
38. Abstract P2-10-03: Genomic markers but not molecular subtypes provide prognostic impact and predict anthracycline efficacy in early triple-negative breast cancer: Results from the prospective WSG PlanB trial
39. Abstract P1-06-06: No age-related outcome disparities according to 21-gene recurrence score groups in early breast cancer patients treated by adjuvant chemotherapy in the prospective WSG PlanB trial
40. Prognostic impact of recurrence score (RS), grade/Ki67 central pathological review, and acycline (A)-free vs. A-containing chemotherapy (CT) on distant and locoregional disease-free survival (DDFS/LRFS) in high clinical risk HER2-early breast cancer (EBC): WSG PlanB trial results
41. De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekly paclitaxel
42. Final analysis of WSG-ADAPT HER2+/HR+ phase-II-trial - efficacy, safety and predictive markers for 12-weeks of neoadjuvant T-DM1 with or without endocrine therapy versus Trastuzumab plus endocrine therapy in HER2-positive hormone-receptor-positive early b
43. Prospective WSG phase III PlanB trial : Clinical outcome at 5 year follow up and impact of 21 Gene Recurrence Score result, central/local-pathological review of grade, ER, PR and Ki67 in HR+/HER2-high risk node-negative and -positive breast cancer
44. Comparison of 12 weeks neoadjuvant Nab-Paclitaxel combined with Carboplatinum vs. Gemcitabine in triple negative breast cancer : WSG-ADAPT TN randomized phase II trial
45. Final analysis of WSG-ADAPT HER2+/HR+ phase II trial : Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant TDM1 with or without endocrine therapy versus trastuzumab+endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer
46. Prognostic impact of recurrence score (RS), grade/Ki67 central pathological review, and acycline (A)-free vs. A-containing chemotherapy (CT) on distant and locoregional disease-free survival (DDFS/LRFS) in high clinical risk HER2- early breast cancer (EBC): WSG PlanB trial results
47. Five-year results of the prospective Phase III WSG PlanB trial confirm prognostic impact of 21-Gene Recurrence Score in high-risk HR+/HER2− early breast cancer (EBC) patients with 1-3 involved lymph nodes
48. Risk assessment by St.Gallen 2013 recommendation and Oncotype DX® : results from the WSG PlanB trial
49. Final analysis of WSG-ADAPT HER2+/HR+ phase-II-trial - efficacy, safety and predictive markers for 12-weeks of neoadjuvant T-DM1 with or without endocrine therapy versus Trastuzumab plus endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer
50. Final analysis of WSG-ADAPT HER2+/HR+ phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant TDM1 with or without endocrine therapy versus trastuzumab plus endocrine therapy in HER2-positive hormone-receptor positive early breast cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.